Navigation Links
Anastrozole Confirmed Superior in Breast Cancer Prevention
Date:12/14/2007

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Anastrozole is more effective than tamoxifen at preventing breast cancer recurrence for periods of at least 10 years in women with hormone-responsive cancers. In addition, the increased risk of fractures that has been seen in some patients being treated with anastrozole disappears after treatment ends.

Speaking at the Thursday session of the San Antonio Breast Cancer Symposium, Professor John Forbes of the University of Newcastle presented the much-anticipated long-term results of the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial that compared 5 years of tamoxifen with 5 years of the aromatase inhibitor anastrozole for the treatment of postmenopausal women with invasive breast cancer.

Hormone-responsive breast cancers require estrogen stimulation in order to grow. Tamoxifen, a synthetic variation of estrogen, binds to hormone receptors on hormone-sensitive cancer cells, preventing estrogen from attaching to the cells. Anastrozole, on the other hand, prevents the manufacture of estrogen by body tissues other than the ovaries (e.g., fat cells), so it is useful for the treatment of hormone-sensitive cancers in postmenopausal women whose ovaries are no longer producing estrogen.

Although previous reports at 33 and 68 months demonstrated that anastrozole was more effective, has fewer serious side effects, and was better tolerated than tamoxifen during the period of treatment, it was not known whether the benefits or side effects associated with anastrozole would persist long term after patients were no longer taking the drug.

After 10 years (5 years after the completion of treatment), patients who had taken anastrozole continued to show reduced rates of tumor recurrence and metastasis compared with patients who had taken tamoxifen. In fact, the relative benefit of anastrozole actually increased compared with results seen immediately after the completion of treatment.

Most striki
'/>"/>

SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Game Commission Announces EHD Confirmed in Fayette County
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
5. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
8. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., , COLLEGE PARK, Md., Nov. 25 /PRNewswire...any developing a shaving cream-like foam that stop...the Most Promising Security Idea category of the G...nnounce today. ,, Selected from more than 100 e...hed their invention at the GSC Security Summit con...
(Date:11/25/2009)..., , NEW YORK, Nov. 25 ...rch report is available in its catalogue: ,, ...e ,, http://www.reportlinker.com/p0164330/Ma...html ,, Rising incidence of breast cancer in i...rincipal factor influencing growth in the mammogra...
(Date:11/25/2009)..., , CHAPEL HILL, N.C., Nov. 25 /PRNewswi... that Prabhavathi Fernandes, president and chief e...y 21st Annual Health Care Conference at 8:50 a.m. ...l in New York City. Dr. Fernandes will provide an...clinical programs for the treatment of drug-resist...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8RealMed Launches New Website 50499 1Cancer survivors at greater risk of birth complications 3B special monitoring needed 50498 1Cancer survivors at greater risk of birth complications 3B special monitoring needed 50498 2Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 1Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 2Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 3
...tisoma plc,(LSE: ASM, US OTC: ATSMY) today announc...ecurrent, platinum-sensitive ovarian cancer.,This ...otherapy,(n=37) with patients receiving chemothera... , * There was no advantage in median time to tumo... control arm * One-year survival,rates were 74% fo...
...he Journal of the,American Society of Clinical Onc...l study conducted by Dr. Siu-Fun Wong, and her,col...enecare(R),caused a statistically significant red...lts from the use of anti-cancer drugs,known as EGF...s,listed on the National Cancer Institute Clinical...
Other Medicine Technology:Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial 2Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial 3Clinical Study Shows Regenecare Relieves Pain and Itching of Skin,Rashes Caused by Widely Used Cancer Drugs 2
(Date:11/26/2009)..., NEW YORK, Nov. 27 With cold and... to employ good practices to control the spread of...e proactive not only to keep ourselves healthy, bu...id Eileen Finerty, RN, MS, CIC (certified in infec...rol and occupational health at Hospital for Specia...
(Date:11/26/2009)...next 25 years, the number of Americans living with... million in 2009 to 44.1 million in 2034. Over the...ple, rising from $113 billion to $336 billion, eve...esearchers based at the University of Chicago repo...he number of those with diabetes covered by Medica...
(Date:11/26/2009)...hat,s too big or too heavy can lead to strains or ...ews) -- There may be nothing wrong with stuffing y...t to do the same thing with your suitcase as you p...e were treated in 2008 in U.S. hospital emergency ... facilities for luggage-related injuries, such as ...
(Date:11/26/2009)... No more letters from the North Po...lized text messages from Santa , ...increase operational efficiencies at the North Pol... keep children all over the globe informed of his ... Santa’s research department have identified...
(Date:11/26/2009)... Research Triangle Dental (RTDenta...th Carolina, today announced the expansion of its ...EER Dentist, Dr. Doug Macmillan. , ...le Dental is pleased to announce that Dr. Doug Mac...ly completed an additional advanced training semin...
Breaking Medicine News(10 mins):Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
...s' will be set up in all colleges in Haryana to cr... people for safe and regular blood donation.// ...y that each Red Ribbon Club would comprise eight t...llocated to each club to educate people about caus...
... Japan, who gave birth to a male heir today, has o...or transplantation to leukemia patients, Masao// N...ld reporters. Prince Akishino and Princess K...rs. Experts say that the Princess' offer may help ...
...t warn nurses when an elderly patient is trying to...rd here to prevent occupants from falling, the dev...s on sensors installed under the mattress. W...s mobile phone, enabling her to arrive at the beds...
...ncy of the Scottish is improving, but the chasm be...as shown.// The figures show the average life expe... 79 and the Scottish male can expect to reach 74 y...improving but this is not happening fast enough. T...
...demy of Pediatrics issued a report on Sept.5, acco...d by lactose-intolerant kids.// Instead, they shou...It is better for children to suffer the intestinal...alifornia San Francisco, the report's principal au...
...tely implantable artificial heart was approved by ...sday.// The artificial heart has been approved for...ll for a heart transplant. Under the FDA's Hum... units of any device per year. The usage of this a...
Other Medicine News:Health News:Lactose-Intolerant kids need to take dairy products to meet nutrient requirements 2Health News:Lactose-Intolerant kids need to take dairy products to meet nutrient requirements 3Health News:First Implantable artificial heart gets FDA’s approva 2
Sterilized TowerPack Refill System D200
Finntip Wide 10-200ul, Sterile
Finntip 200 Ext (Sterile)
MBP 200MicroPoint Design
Medicine Products: